Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, reposted from ICMR-NIRBID on LinkedIn:
”Reposting with immense pride and gratitude
Truly delighted to see our ‘Factor VIII Inhibitor Point-of-Care Diagnostic’ successfully transferred at Science–Tech’ on National Technology Day 2026.
Grateful to my wonderful team – Sharda Shanbhag, Sweta Kaskar, and Moni Singh – and honoured that this milestone was achieved in the presence of Hon’ble Minister Dr Jitendra Singh .
Proud to see this innovation licensed to Meril Pvt Ltd – bringing us a step closer to accessible and affordable hemophilia diagnostics.”
Quoting ICMR-National Institute for Research on Blood and Immune Disorders, (ICMR-NIRBID)‘s post:
”ICMR–NIRBID is especially proud to highlight the successful technology transfer of its novel ‘Factor VIII Inhibitor Point-of-Care Diagnostic’, developed by Rucha Patil, Sharda Shanbhag, Sweta Kaskar, and Moni Singh, at the national programme Science–Tech’ held on the occasion of National Technology Day 2026 at BRIC–National Institute of Immunology, in the presence of Jitendra Singh, Hon’ble Minister of State (Independent Charge), Ministry of Science and Technology and Ministry of Earth Sciences; MoS, PMO; Ministry of Personnel, Public Grievances and Pensions; Department of Atomic Energy; and Department of Space, Government of India.
This innovation has been licensed to Meril Life Sciences, marking a significant advancement toward enhancing accessible and timely diagnostics for hemophilia care.
The novel FVIII inhibitor POCT is a low-cost, point-of-care lateral flow assay based on gold nanoparticle technology, enabling rapid detection of FVIII inhibitors at approximately one-twentieth the cost of the gold-standard assay, while remaining unaffected by non-factor therapies.”

Stay updated with Hemostasis Today.
-
Jun 26, 2026, 02:06Giovanni Merlino: Scientific Progress in Secondary Stroke Prevention at Udine Stroke Congress 2026
-
Jun 26, 2026, 01:48Michael Stark: Highlights from ISBT 2026 on RBC Transfusion and NEC in Neonates
-
Jun 25, 2026, 23:08Geert Verheyden: Belgium’s Vision for Better Stroke Care Across the Continuum
-
Jun 25, 2026, 21:04Else Charlotte Sandset: Pleasure to Welcome Polish Delegation to Oslo University Hospital Stroke Tour
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective
-
Jun 25, 2026, 19:27Srikanth R.: Don’t Ignore Your Health While Chasing Success
-
Jun 25, 2026, 19:27Jamie Nash: Delighted to Receive the BBTS Race and Sanger Award 2026